Manufacturing Establishments1
FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.
Taro Pharmaceuticals U.S.A., inc.
600072078
Products1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Bowel Prep kit
Product Details
Drug Labeling Information
Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.
INDICATIONS & USAGE SECTION
Highlight: Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult patients. ( 1)
1 INDICATIONS AND USAGE
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adult patients.
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
DOSAGE & ADMINISTRATION SECTION
Highlight: Preparation and Administration ( 2.2)
- Must dilute in water prior to ingestion.
- Administration of two bottles of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is required for a complete preparation for colonoscopy. One bottle is equivalent to one dose.
- Must consume additional water after each dose.
- Stop consumption of all fluids at least 2 hours before the colonoscopy.
Recommended Dosage and Administration
- Split-Dose (two-day) regimen consists of two doses of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution: first dose during the evening prior to colonoscopy and second dose the next day, during the morning of colonoscopy. ( 2.1, 2.3)
- Recommended sodium sulfate, potassium sulfate, and magnesium sulfate oral solution dosage is: ***Adults:**Two 6-ounce doses. ( 2.3)
- For complete information on preparation before colonoscopy and administration of the dosage regimen, see full prescribing information. ( 2.1, 2.2, 2.3)
2 DOSAGE AND ADMINISTRATION
2.1 Dosage and Administration Overview
Administration of two bottles of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and additional water is required for a complete preparation for colonoscopy. One bottle of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is equivalent to one dose. Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is supplied in one dosage strength [see Dosage Forms and Strengths (3)] . The recommended dosage is:
***Adults:**Two 6-ounce doses [see Dosage and Administration (2.3)] .
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
2.2 Important Preparation and Administration Instructions
- Correct fluid and electrolyte abnormalities before treatment with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution [see Warnings and Precautions (5.1)]
- Must dilute sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in water before ingestion.
- Must consume additional water after each dose of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- On the day before colonoscopy, consume only a light breakfast or clear liquids (e.g., water, strained fruit juice without pulp, lemonade, plain coffee or tea, chicken broth, gelatin dessert without fruit). On the day of the colonoscopy only consume clear liquids up to two hours prior to colonoscopy.
- Do not eat solid food or drink milk or eat or drink anything colored red or purple.
- Do not drink alcohol.
- Do not take other laxatives while taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- Do not take oral medications within one hour of starting each dose of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution [see Drug Interactions (7.2)] .
- Stop consumption of all fluids at least 2 hours prior to the colonoscopy.
2.3 Recommended Dosage and Administration for Adults
The recommended Split-Dose (two-day) regimen foradultsconsists of two 6-ounce doses of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution: the first dose during the evening prior to colonoscopy and the second dose the next day, during the morning of the colonoscopy.
Each dose consists of one bottle of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution with additional water. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts. The following are recommended dosage and administration instructions for adults:
Dose 1- On the Day Prior to Colonoscopy:
- May consume a light breakfast, or only clear liquids (no solid food).
- In the evening before the procedure, pour the contents of one bottle of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution into the mixing container provided.
- Add cool drinking water to the 16-ounce fill line on the container, mix, and drink the entire amount.
- Drink two additional containers filled with water to the 16-ounce fill line over the next hour.
Dose 2 - Day of Colonoscopy:
- Continue to consume only clear liquids.
- In the morning (10 to 12 hours after the evening dose) on the day of the procedure, pour the contents of the second bottle of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution into the mixing container provided.
- Add cool drinking water to the 16-ounce fill line on the container, mix, and drink the entire amount.
- Drink two additional containers filled with water to the 16-ounce fill line over the next hour.
- Complete all solution of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and required water at least two hours prior to colonoscopy.
DOSAGE FORMS & STRENGTHS SECTION
Highlight: * Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution**(for adults):**Two bottles each containing 6 ounces of an oral solution of 17.5 grams sodium sulfate, 3.13 grams potassium sulfate, and 1.6 grams magnesium sulfate. ( 3)
3 DOSAGE FORMS AND STRENGTHS
- Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution**(for adults):**Two bottles each containing 6 ounces of an oral solution of 17.5 grams sodium sulfate, 3.13 grams potassium sulfate, and 1.6 grams magnesium sulfate as a clear to slightly hazy liquid.
When diluted as directed, the solution is clear and colorless.
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
CONTRAINDICATIONS SECTION
Highlight: * Gastrointestinal obstruction or ileus ( 4, 5.6)
- Bowel perforation ( 4, 5.6)
- Toxic colitis or toxic megacolon ( 4)
- Gastric retention ( 4)
- Hypersensitivity to any ingredient ( 4)
4 CONTRAINDICATIONS
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is contraindicated in the following conditions:
- Gastrointestinal obstruction or ileus [see Warnings and Precautions (5.6)]
- Bowel perforation [see Warnings and Precaution (5.6)]
- Toxic colitis or toxic megacolon
- Gastric retention
- Hypersensitivity to any of the ingredients in sodium sulfate, potassium sulfate, and magnesium sulfate oral solution
WARNINGS AND PRECAUTIONS SECTION
Highlight: * Risk of fluid and electrolyte abnormalities:Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use. ( 5.1, 7.1)
- Cardiac arrhythmias:Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. ( 5.2)
- Seizures:Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold. ( 5.3, 7.1)
- Patients with renal impairment or taking concomitant medications that affect renal function:Use caution, ensure adequate hydration and consider laboratory testing. ( 5.4, 7.1)
- Suspected GI obstruction or perforation:Rule out the diagnosis before administration. ( 4, 5.6)
- Patients at risk for aspiration:Observe during administration. ( 5.7)
5 WARNINGS AND PRECAUTIONS
5.1 Serious Fluid and Serum Chemistry Abnormalities
Advise all patients to hydrate adequately before, during, and after the use of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. If a patient develops significant vomiting or signs of dehydration after taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN).
Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. Use sodium sulfate, potassium sulfate, and magnesium sulfate oral solution with caution in patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)] .
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution can cause temporary elevations in uric acid [see Adverse Reactions (6.1)] . Uric acid fluctuations in patients with gout may precipitate an acute flare. The potential for uric acid elevation should be considered before administering sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to patients with gout or other disorders of uric acid metabolism.
5.2 Cardiac Arrhythmias
There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing sodium sulfate, potassium sulfate, and magnesium sulfate oral solution for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
5.3 Seizures
There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.
Use caution when prescribing sodium sulfate, potassium sulfate, and magnesium sulfate oral solution for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia [see Drug Interactions (7.1)] .
5.4 Use in Patients with Risk of Renal Injury
Use sodium sulfate, potassium sulfate, and magnesium sulfate oral solution with caution in patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) [see Drug Interactions (7.1)] . These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and consider performing baseline and post- colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Use in Specific Populations (8.6)] .
5.5 Colonic Mucosal Ulcerations and Ischemic Colitis
Osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and sodium sulfate, potassium sulfate, and magnesium sulfate oral solution may increase these risks [see Drug Interactions (7.3)] . Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).
5.6 Use in Patients with Significant Gastrointestinal Disease
If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering sodium sulfate, potassium sulfate, and magnesium sulfate oral solution [see Contraindications (4)] .
Use with caution in patients with severe active ulcerative colitis.
5.7 Aspiration
Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. Observe these patients during administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. Use with caution in these patients.
USE IN SPECIFIC POPULATIONS SECTION
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on sodium sulfate, potassium sulfate, and magnesium sulfate oral solution use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproductive studies have not been conducted with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
8.2 Lactation
Risk Summary
There are no data available data on the presence of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and any potential adverse effects on the breastfed child from sodium sulfate, potassium sulfate, and magnesium sulfate oral solution or from the underlying maternal condition.
8.4 Pediatric Use
The safety and effectiveness of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in pediatric patients less than 12 years of age have not been established.
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
8.5 Geriatric Use
Of the 375 patients who received sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in clinical trials, 94 (25%) were 65 years of age or older, and 25 (7%) were 75 years of age or older. No overall differences in safety or effectiveness of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution, administered as the recommended split- dose (2-day) regimen, were observed between geriatric patients and younger patients. Geriatric patients reported more vomiting when sodium sulfate, potassium sulfate, and magnesium sulfate oral solution was given as a one-day preparation (not a recommended regimen).
Elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities [see Warnings and Precautions (5.1)].
8.6 Renal Impairment
Use sodium sulfate, potassium sulfate, and magnesium sulfate oral solution with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after use of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and consider performing baseline and post- colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Warnings and Precautions (5.4)] .
ADVERSE REACTIONS SECTION
Highlight: Most common adverse reactions are:
- Adults (>2%): overall discomfort, abdominal distention, abdominal pain, nausea, and vomiting. ( 6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6 ADVERSE REACTIONS
The following important adverse reactions for bowel preparations are described elsewhere in the labeling:
- Serious Fluid and Serum Chemistry Abnormalities [see Warnings and Precautions (5.1)]
- Cardiac Arrhythmias [see Warnings and Precautions (5.2)]
- Seizures [see Warnings and Precautions (5.3)]
- Use in Patients with Risk of Renal Injury [see Warnings and Precautions (5.4)]
- Colonic Mucosal Ulceration and Ischemic Colitis [see Warnings and Precautions (5.5)]
- Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.6)]
- Aspiration [see Warnings and Precautions (5.7)]
6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in clinical studies of another drug and may not reflect the rates observed in practice.
Adults
The safety of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution was evaluated in a multi-center, randomized, active controlled trial in 379 adult patients undergoing colonoscopy [see Clinical Studies (14)] .
Most Common Adverse Reactions
Table 1 shows the most common adverse reactions reported in at least 2% of patients receiving sodium sulfate, potassium sulfate, and magnesium sulfate oral solution or the control (a bowel prep containing polyethylene glycol and electrolytes (PEG + E)) administered in split-dose (2-day) regimens.
Table 1: Common Adverse Reactions *in Adult Patients Undergoing Colonoscopy in a Randomized, Active Controlled Trial
Split-Dose (2-Day) Regimen | ||
---|---|---|
Symptom |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
PEG + E product |
| ||
Overall Discomfort |
54 |
67 |
Abdominal Distension |
40 |
52 |
Abdominal Pain |
36 |
43 |
Nausea |
36 |
33 |
Vomiting |
8 |
4 |
Laboratory Abnormalities
Table 2 shows the most common laboratory abnormalities (at least 10% in either treatment group and more than 2% difference between groups) for patients who developed new abnormalities of important electrolytes and uric acid after completing the bowel preparation with either sodium sulfate, potassium sulfate, and magnesium sulfate oral solution or PEG+E administered as a split- dose (2-day) regimen.
Table 2: Adult Patients with Normal Baseline Serum Chemistry with A Shift to an Abnormal Value While on the Split-Dose (2-Day) Regimen *
Day of Colonoscopy |
Day 30 | ||
---|---|---|---|
| |||
Bicarbonate (low) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
20 (13) |
7(4) |
PEG + Electrolytes |
24 (15) |
4 (3) | |
Bilirubin, total (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
14 (9) |
0 (0) |
PEG + Electrolytes |
20 (12) |
3 (2) | |
BUN (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
2 (2) |
14 (11) |
PEG + Electrolytes |
4(3) |
19 (15) | |
Calcium (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
16 (10) |
8 (5) |
PEG + Electrolytes |
6 (4) |
6 (4) | |
Chloride (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
4 (2) |
6 (4) |
PEG + Electrolytes |
20 (12) |
6 (4) | |
Osmolality (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
8 (6) |
NA |
PEG + Electrolytes |
19 (13) |
NA | |
Uric acid (high) |
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution |
27 (24) |
13 (12) |
PEG + Electrolytes |
12 (10) |
20 (17) |
Less Common Adverse Reactions
AV Block (1 case) and CK increase.
Adverse Reactions with Unapproved Use
In another study of 408 adult patients, higher rates of the following adverse reactions and laboratory abnormalities were reported in patients treated with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution as an evening-only (1-day) regimen compared to the split-dose (2-day) regimen.
- overall discomfort, abdominal distention, nausea, and vomiting
- total bilirubin (high), BUN (high), creatinine (high), osmolality (high), potassium (high) and uric acid (high)
Administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in an evening-only (1-day) dosing regimen is not recommended.
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
OVERDOSAGE SECTION
10 OVERDOSAGE
Overdosage of more than the recommended dose of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances [see Warnings and Precautions (5.1, 5.2, 5.3)] . Monitor for fluid and electrolyte disturbances and treat symptomatically.
INFORMATION FOR PATIENTS SECTION
17 PATIENT COUNSELING INFORMATION
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide). Instruct patients or caregivers:
- Must dilute sodium sulfate, potassium sulfate, and magnesium sulfate oral solution before ingestion.
- Must consume additional water after each dose of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- On the day before colonoscopy, consume only a light breakfast or clear liquids (e.g., water, apple or orange juice without pulp, lemonade, coffee, tea, or chicken broth). On the day of the colonoscopy only consume clear liquids up to two hours prior to colonoscopy.
- Two doses of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution are required for a complete preparation for colonoscopy .One bottle of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is equivalent to one dose.
- Do not to take other laxatives while taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- Do not eat solid food or drink milk or eat or drink anything colored red or purple.
- Do not drink alcohol.
- Do not take oral medications within one hour of starting each dose of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution.
- If taking tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine, take these medications at least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution [see Drug Interactions (7.2)] .
- Stop consumption of all fluids at least 2 hours prior to colonoscopy.
- Contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution or if they experience cardiac arrhythmias or seizures [see Warnings and Precautions (5.1, 5.2, 5.3)] .
SPL MEDGUIDE SECTION
This Medication Guide has been approved by the U.S. Food and Drug Administration. | ||||
Revised: November 2023 5201578-1123-01 | ||||
MEDICATION GUIDE | ||||
Read and understand this Medication Guide instructionsat least 2 days beforeyour colonoscopy and again before you start taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. | ||||
What is the most important information I should know about sodium sulfate,
potassium sulfate, and magnesium sulfate oral solution? | ||||
*Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause: *abnormal heartbeats that can cause death ***seizures.**This can happen even if you have never had a seizure. *kidney problems | ||||
Your chance of having fluid loss and changes in body salts with sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is higher if you: | ||||
| ||||
Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution: | ||||
|
| |||
See "What are the possible side effects of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution?" for more information about side effects. | ||||
What is sodium sulfate, potassium sulfate, and magnesium sulfate oral
solution? | ||||
Do nottake sodium sulfate, potassium sulfate, and magnesium sulfate oral solution if your healthcare provider has told you that you have: | ||||
| ||||
Before taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution, tell your healthcare provider about all of your medical conditions, including if you: | ||||
| ||||
**Tell your healthcare provider about all the medicines you take,**including
prescription and over-the-counter medicines, vitamins, and herbal supplements. | ||||
Especially tell your healthcare provider if you take: | ||||
| ||||
The following medicines should be taken at least 2 hours before starting sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and not less than 6 hours after taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution: | ||||
| ||||
Ask your healthcare provider or pharmacist for a list of these medicines if
you are not sure if you are taking any of the medicines listed above. | ||||
How should I take sodium sulfate, potassium sulfate, and magnesium sulfate
oral solution? | ||||
| ||||
*While taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution, do not: * take any other laxatives. * take any medicines by mouth (oral) within 1 hour of starting sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. * eat solid foods, drink dairy (such as milk), or drink alcohol while taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and until after your colonoscopy * eat or drink anything colored red or purple. | ||||
Contact your healthcare provider right awayif after taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution you have severe vomiting, signs of dehydration, changes in consciousness such as feeling confused, delirious or fainting (loss of consciousness) or seizures after taking sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. | ||||
What are the possible side effects of sodium sulfate, potassium sulfate, and
magnesium sulfate oral solution? | ||||
| ||||
|
|
| ||
***Ulcers of the bowel or bowel problems (ischemic colitis).**Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding. | ||||
The most common side effects of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution in adults include: | ||||
|
| |||
These are not all the possible side effects of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. | ||||
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||||
How should I store sodium sulfate, potassium sulfate, and magnesium sulfate oral solution? | ||||
| ||||
Keep sodium sulfate, potassium sulfate, and magnesium sulfate oral solution and all medicines out of the reach of children. | ||||
General information about the safe and effective use of sodium sulfate, potassium sulfate, and magnesium sulfate oral solution. | ||||
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sodium sulfate, potassium sulfate, and magnesium sulfate oral solution for a condition for which it was not prescribed. Do not give sodium sulfate, potassium sulfate, and magnesium sulfate oral solution to other people, even if they are going to have the same procedure you are. It may harm them. You can ask your pharmacist or healthcare provider for information about sodium sulfate, potassium sulfate, and magnesium sulfate oral solution that is written for healthcare professionals. | ||||
What are the ingredients in sodium sulfate, potassium sulfate, and magnesium
sulfate oral solution? | ||||
**Active ingredients:**sodium sulfate, potassium sulfate and magnesium sulfate | ||||
**Inactive ingredients:**citric acid, grape flavor, malic acid, mixed berry flavor natural, purified water, sodium benzoate and sucralose | ||||
Pediatric use information is approved for Braintree Laboratories, Inc.'s SUPREP BOWEL PREP KIT (sodium sulfate, potassium sulfate, and magnesium sulfate) oral solution. However, due to Braintree Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. | ||||
Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761 |
SPL UNCLASSIFIED SECTION
Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761
Dist. by:**Taro Pharmaceuticals U.S.A., Inc.,**Hawthorne, NY 10532
TARO is a registered trademark of Taro Pharmaceuticals U.S.A., Inc. and/or its
affiliates.
All other trademarks are the property of their respective owners.
Revised: November 2023
5201578-1123-01
Dispense with Mediation Guide available at https://www.taro.com/usa- medication-guides